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Abstract: Cascade cyclization of bromoenynes bearing an aryl 
group with catalytic Pd(OAc)2 and Cs2CO3 led to direct 
construction of tri- or tetracyclic heterocycles. Direct arylation 
of a pyrrole, furan or thiophene ring in the cascade reaction 
affords the corresponding fused heteroarenes in moderate to 
good yields. 
Key words: tandem reaction, palladium, polycycles, fused-ring 
systems, ring closure 
The development of cascade reactions that realize 
step-economical synthesis of complex compounds by 
multiple bond formation represents one of the most 
attractive subjects in modern organic chemistry.1 
Another challenge in this area is to improve atom 
economy by minimizing waste product formation.2 C-
H bond activation (including direct arylation), which 
avoids pre-activation of the substrate and thus 
minimizes the production of waste, is an important 
strategy for this purpose.3 As a result, considerable 
attention has been paid recently to catalytic cascade 
reactions including a C-H bond activation step.4  
Palladium catalysts are well known to promote a 
variety of transformations including C-H bond 
activation. Several palladium-catalyzed cascade 
reactions have been reported recently, including 
carbopalladation onto a carbon-carbon multiple bond 
followed by C-H bond activation to form cyclic 
products.4,5 Reactions involving carbopalladation onto 
a carbon-carbon triple bond are especially useful for 
direct construction of fused aromatic ring systems6,7 
such as oxindoles,6a,6b fluorenes,6c indoles,6d 
phenanthrenes,6e biarylidenes,7a,7b acenaphthylenes,7c 
and fused fulvenes.7d We recently found that 
palladium-catalyzed cascade cyclization of 
bromoenynes 1 provides direct access to 
benzoisoindole derivatives 2 (Scheme 1).8 This 
reaction proceeds through oxidative addition of a 
bromoenyne 1 to palladium(0), carbopalladation, and 
aromatic C-H bond activation. Herein, our detailed 
studies on this cascade cyclization including aromatic 
C-H bond activation for the synthesis of various tri- 
and tetracyclic heterocycles are reported. A reaction 
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Scheme 1  Synthesis of Isoindoles by Palladium-Catalyzed 
Cascade Reaction via C-H Bond Activation 
The cinnamylamine-type bromoenynes 11 required for 
the cascade reaction were prepared according to the 
general route shown in Scheme 2. Carreira 
asymmetric alkynylation9 of aldehydes 5 with alkynes 
6 gave propargylic alcohols 7, which were converted 
to the corresponding protected propargylic amines 8 
by Mitsunobu reaction with Boc-amides followed by 
acid treatment. In some cases, racemic 
propargylamines, which were readily prepared by 
reaction of lithium acetylide with aldehydes followed 
by amination, were used. A second Mitsunobu 
condensation with 2-bromocinnamyl alcohols 10, 
which were obtained by Wittig reaction of aldehydes 9 
followed by reduction with DIBAL-H, afforded the 
desired bromoenynes 11 in good yields. Other 
substrates were also prepared using a similar protocol 
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Scheme 2  General Syntheses of Substrates. Abbreviations: NME = 
N-methylephedrine, DIAD = diisopropyl azodicarboxylate 
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First, the reaction conditions were optimized using 
bromoenyne 11a (Table 1). After considerable 
experimentation, it was found that the conditions used 
by Oh et al.10 [cat. Pd(PPh3)4, Cs2CO3, EtOH] for a 
cascade cyclization–cross-coupling reaction of 2-
bromo-1,6-enynes with an arylboronic acid promoted 
the desired bis-cyclization to give 12a, albeit in low 
yield (26%, entry 1). Fortunately, use of Pd(OAc)2 
instead of Pd(PPh3)4 produced 12a in 74% yield (entry 
2). Decreasing the catalyst loading to 2 mol % slightly 
decreased the yield (64%, entry 3). A similar result 
was obtained using Pd2(dba)3·CHCl3 as the catalyst 
(entry 5). Among several solvents examined, EtOH 
was the most effective (entries 3, 6, and 7). Other 
bases such as K2CO3 and NaOAc proved ineffective 
for the reaction.11  














entry catalyst (mol %) solvent time (h) 
yield 
(%)b 
1 Pd(PPh3)4 (6) EtOH 1 26 
2 Pd(OAc)2 (6) EtOH 2.5 74 
3 Pd(OAc)2 (2) EtOH 7 64 
4 Pd(dppf)2Cl2 (2) EtOH 3.5 38 
5 Pd2(dba)3·CHCl3 (2) EtOH 5 59 
6c Pd(OAc)2 (2) DMF 21 35 
7 Pd(OAc)2 (2) dioxane 21 27 
a Reactions were performed using Cs2CO3 (2 equiv).  b Isolated 
yields.  c The reaction was performed at 100 °C.  
 
The reactions of various cinnamylamine-type enynes 
11 using the optimized reaction conditions shown in 
entry 3 (Table 1) were investigated. The results of 
these reactions are summarized in Table 2. The 
influence of the substituent at the alkyne terminus was 
examined using N-tosylamides 11b–f. 2-
Hydroxypropan-2-yl, n-butyl, and unsubstituted 
derivatives 11b–d gave the corresponding bis-
cyclization products 12b–d in 56–79% yield (entries 
1–3). On the other hand, benzyloxymethyl derivative 
11e gave a complex mixture of unidentified products 
(entry 4). For an unclear reason, phenyl substitution 
also had a negative effect on the reaction, giving 12f 
in just 27% yield (entry 5). Using different 
sulfonamide moieties (Ts vs. Ms) was relatively 
unimportant (Table 2, entry 3 vs. 6, and Table 2, entry 
1 vs. Table 1, entry 3). In contrast, the reaction is 
sensitive to the substituent at the propargylic position 
(entries 7–11); unfortunately, substitution with a 
phenyl group was not tolerated (entry 7). The presence 
of a relatively bulky substituent such as an isopropyl 
or 1-siloxyethyl group at this position decreased the 
reaction yield (entries 10 and 11). When tert-butyl 
derivative 11j was used (Scheme 3), only the 
monocyclization product 13j was obtained in 7% 
yield; the desired bis-cyclization product did not form. 
These bulky substituents might hamper the access of 
the palladium(II) intermediate of type 3 (Scheme 1) to 
the alkyne moiety. It should be noted that enynes 11m 
and 11n without propargylic or nitrogen substitution 
formed elimination products 14 (Scheme 3).12 From 
these observations, the presence of both a substituent 
with appropriate bulkiness at the propargylic position 
and at the nitrogen atom are important for the cascade 
cyclization to proceed. Methoxy substitution at the 
para-position of the benzene ring decreased the 
reaction yield (37%, entry 13), while meta-methoxy 
substitution was tolerated (57%, entry 12).  
Table 2 Synthesis of Benzoisoindole Derivativesa  






















11b (R = CMe2OH)
11c (R = n-Bu)
11d (R = H)
11e (R = CH2OBn)












11h (R = Ph)


















11k (R = n-Pent)





















11p (R1 = OMe, R2 = H)















a Unless otherwise noted, reactions were carried out using 
Pd(OAc)2 (2 mol %) and Cs2CO3 (2 equiv) in EtOH under reflux.  
b Isolated yields.  c A complex mixture of unidentified products 











































Scheme 3  Unsuccessful Results using Bromoenynes 11j,m,n. 
Table 3 Synthesis of Tricyclic Heterocyclesa  









































10 mol %, DMF, 72 h
20 mol %, DMF, 2 h
10 mol %, DMF, 2 h
20 mol %, DMF, 2 h
10 mol %, EtOH, 12 h
10 mol %, EtOH, 12 h
10 mol %, DMF, 3 h
15b (R = Ts)
15b (R = Ts)
15c (R = Mts)
15c (R = Mts)
15c (R = Mts)
15d (R = SO2NMe2)
15d (R = SO2NMe2)




a The reactions were carried out using Pd(OAc)2 and Cs2CO3 (2 
equiv) in EtOH (under reflux) or DMF (at 120 °C).  b Catalyst 
loading, reaction solvent, and reaction time are shown.  c Isolated 
yields.  d The starting material was recovered (27%).  
Abbreviation: Mts = 2,4,6-trimethylbenzenesulfonyl. 
 
To expand the reaction to construct various 
heterocyclic ring systems, the direct arylation13 of 
heterocyclic substrates 15a–e was investigated (Table 
3). The reaction of furan-substituted enyne 15a was 
complete within 2 h to afford furo[2,3-f]isoindole 16a 
in moderate yield (43%, entry 1). Bromoenynes 15b–e 
bearing a pyrrole ring exhibited relatively low 
reactivity and thus required an increased loading of 
the palladium catalyst (entries 2–9). For example, the 
reaction of tosylamide 15b with 10 mol % Pd(OAc)2 
and Cs2CO3 in DMF did not reach completion within 
72 h, giving the desired tetrahydropyrrolo[3,4-f]indole 
16b in 27% yield along with the recovered starting 
material (entry 2). In contrast, the yield of 16b was 
improved to 75% when 20 mol % of the catalyst was 
used (entry 3). Similar results were obtained using N-
Mts derivative 15c (Mts = 2,4,6-
trimethylbenzenesulfonyl, entries 4 and 5). It is worth 
noting that DMF was the solvent of choice for the 
reaction of protected pyrroles 15b and 15c because the 
reaction in EtOH was relatively inefficient and caused 
decomposition of the starting material (entry 6). When 
using electron-rich sulfonamide 15d, the 
decomposition of the substrate in EtOH was 
suppressed to some extent, and the desired fused 
indole 16d was produced in 52% yield (entry 7). The 
2-position of the pyrrole was less reactive toward 
direct arylation than the 3-position in this cascade 
reaction (entry 3 vs. entry 9). 
Table 4 Synthesis of Tetracyclic Heterocyclesa  


































5 mol %, DMF, 18 h
5 mol %, DMF, 3 h
5 mol %, DMF, 4 h
5 mol %, EtOH, 1 h
10 mol %, EtOH, 36 h
17a (R = Ts)
17b (R = Mts)
17c (R = CO2Me)
17c (R = CO2Me)
17d (R = Me)
6 18e (49%)2 mol %, EtOH, 3 h17e








8 18g (43%)5 mol %, DMF, 5 hf17g
n-Bu
a Reactions were carried out using Pd(OAc)2 and Cs2CO3 (2 
equiv) in EtOH (under reflux) or DMF (at 120 °C).  b Catalyst 
loading, reaction solvent, and reaction time are shown.  c Isolated 
yields.  d A complex mixture of unidentified products was 
formed.  e The demethoxycarbonylation product was obtained 
(67%).  f 2 h with 2 mol % catalyst and a further 3 h with an 
additional 3 mol % catalyst. 
Abbreviation: Mts = 2,4,6-trimethylbenzenesulfonyl. 
 
The synthesis of tetracyclic fused ring systems was 
investigated next (Table 4). Among the protected 
indole-derived bromoenynes 17a–c (entries 1–4), 
tosylate 17a proved the most efficient substrate for the 
cascade reaction, giving the desired 
tetrahydropyrrolo[3,4-b]carbazole 18a upon reaction 
in DMF (entry 1). The reaction of carbamate 17c in 
EtOH only promoted demethoxycarbonylation of the 
substrate  (entry 4). Interestingly, the electron-rich N-
methylindole-derived enyne 17d was less reactive, 
affording 18d in 43% yield using an increased loading 
of the palladium catalyst (10 mol %, entry 5). These 
results suggest that the direct arylation of indole 
derivatives 17 proceeds through a concerted 
metalation-deprotonation (CMD) pathway rather than 
electrophilic aromatic substitution (SEAr).14 The 
reaction of benzothiophen-3-yl- and benzofuran-2-
ylenynes 17e and 17f produced the corresponding 
benzothiophene- and benzofuran-fused isoindoles 18e 
and 18f, respectively, in moderate yields (entries 6 and 
7). 2,3-Dihydronaphtho[2,3-f]isoindole 18g was 
obtained in 43% yield by activation of the naphthalene 
C-H bond (entry 8). 
Finally, construction of an indane skeleton using 
malonate congeners 19 was investigated (Table 5). 
The reaction of 19a with Pd(OAc)2 in EtOH produced 
tricyclic carbocycle 20a in 68% yield (entry 2). Other 
palladium catalysts such as Pd2(dba)3·CHCl3 (entry 3) 
and Pd(PPh3)4 (entry 4) were less effective. The 
presence of a substituent at the propargylic position 
was important to promote the desired cascade 
cyclization also in the reactions using malonate 
derivatives.12 The reaction of pyrrole-derived 
malonate 19b in DMF at 140 °C resulted in the 
formation of cyclopenta[f]indole derivative 20b in low 
yield (35%, entry 5).  
Table 5 Synthesis of Indane Derivativesa 






















5 mol %, DMF, 6 h
5 mol %, EtOH, 2 h
5 mol %,e DMF, 4 h















a Unless otherwise stated, reactions were performed using 
Pd(OAc)2 and Cs2CO3 (2 equiv) in EtOH (under reflux) or DMF 
(at 120 °C).  b Catalyst loading, reaction solvent, and reaction 
time are shown.  c Isolated yields.  d A complex mixture of 
unidentified products was formed.  e Pd2(dba)3·CHCl3 was used. f 
Pd(PPh3)4 was used.  g The reaction was conducted at 140 °C. 
 
In conclusion, we have developed a palladium-
catalyzed cascade for cyclization of bromoenynes. 
The reaction proceeds through carbopalladation onto a 
carbon-carbon triple bond and C-H bond activation of 
a benzene ring, leading to the direct construction of 
isoindole derivatives. The presence of a propargylic 
substituent is quite important for the progress of the 
reaction. Direct arylation of heteroarenes such as 
pyrrole, furan, thiophene and their benzene-fused 
rings allows various types of tri- and tetracyclic 
heterocycles to be produced from readily prepared 
enynes.  
 
Melting points are uncorrected. Nominal (LRMS) and 
exact mass (HRMS) spectra were recorded on a JEOL 
JMS-700 or JMS-600 mass spectrometer. 1H NMR 
spectra were recorded in CDCl3. Chemical shifts are 
reported in parts per million downfield from internal 
Me4Si (s = singlet, d = doublet, dd = double doublet, 
ddd = doublet of double doublet, t = triplet, dt = 
double triplet, tt = triple triplet, q = quartet, m = 
multiplet). Optical rotations were measured in CHCl3 
with a JASCO DIP-360 digital polarimeter. For flash 
chromatography, silica gel 60 H (silica gel for thin-
layer chromatography, Merck) or silica gel 60 (finer 
than 230 mesh, Merck) was employed. 
 
General procedure for Synthesis of Bromoenynes 
(11) by Condensation of Propargyl Amine 
Derivatives (8) with 3-Aryl-2-bromoprop-2-en-1-
ols (10) 
To a stirred mixture of protected propargylic amine 8 
(ca. 3 mmol), alcohol 10 (2.2 equiv), and PPh3 (2.2 
equiv) in THF (30 mL) was added dropwise 
diisopropyl azodicarboxylate (DIAD; 2.2 equiv) at 
0 °C. The mixture was stirred for 4 h at room 
temperature and concentrated under reduced pressure. 
The residue was purified by column chromatography 
over silica gel with an eluent of n-hexane–EtOAc to 
give 11.  
 
General Procedure for the Palladium-Catalyzed 
Cascade Cyclization of Bromoenynes: Synthesis of 
(1R)-1-Cyclohexyl-9-(2-hydroxypropan-2-yl)-2-
methylsulfonyl-2,3-dihydro-1H-benzo[f]isoindole 
(12a) (Table 1, Entry 3) 
A mixture of 11a (124 mg, 0.265 mmol), Cs2CO3 (173 
mg, 0.531 mmol), and Pd(OAc)2 (1.2 mg, 0.0531 
mmol; 2 mol %) in EtOH (1.5 mL) was heated under 
reflux for 7 h. After cooling the mixture, saturated 
NH4Cl was added. The mixture was then extracted 
with EtOAc and dried over MgSO4. Concentration 
under reduced pressure gave an oily residue, which 
was purified by column chromatography over silica 
gel with n-hexane–EtOAc (10:1) to give 12a (65.7 mg, 
64% yield) along with an unidentified minor product 
(2.5 mg, 3% yield). 
Compound 12a: colorless oil; [α]28D +31.4 (c 0.62, 
CHCl3). 
IR (KBr): 3545 (OH), 1336 (NSO2), 1153 cm–1 
(NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.90–1.28 (m, 5H), 
1.58–1.85 (m, 6H), 1.96 (s, 3H, CMe), 2.03 (s, 3H, 
CMe), 2.55 (s, 3H, SO2Me), 4.65 (dd, J = 16.8, 1.2 Hz, 
1H, NCHH), 4.80 (dd, J = 16.8, 1.2 Hz, 1H, NCHH), 
5.97 (d, J = 1.2 Hz, 1H, 1-H), 7.42–7.50 (m, 2H, Ar), 
7.61 (s, 1H, Ar), 7.79–7.82 (m, 1H, Ar), 8.25 (dd, J = 
9.9, 2.7 Hz, 1H, Ar). 
13C NMR (67.5 MHz, CDCl3): δ = 26.2, 26.3, 26.7 
(2C), 31.4, 32.6, 34.2 (2C), 47.0, 53.4, 71.9, 75.2, 
120.8, 125.0, 125.1, 126.5, 129.0, 130.3, 134.6, 136.4, 
137.3, 139.0. 
MS (FAB): m/z (%) = 388 [MH+] (53), 154 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C22H30NO3S: 
388.1946; found: 388.1948. 
Minor product: colorless oil; [α]22D –114 (c 0.14, 
CHCl3). 
IR (KBr): 3519 (OH), 1338 (NSO2), 1159 cm–1 
(NSO2). 
1H NMR (300 MHz, CDCl3): δ = 1.10 (s, 3H, CMe), 
1.15–1.96 (m, 12H), 1.31 (s, 3H, CMe), 2.79 (s, 3H, 
SO2Me), 4.47 (d, J = 1.2 Hz, 2H), 5.84 (s, 1H, C=CH), 
7.13–7.27 (m, 5H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 26.1, 26.2, 26.3, 27.5, 
28.8, 29.1, 29.4, 34.5, 43.2, 49.7, 67.6, 70.8, 113.8, 
127.4 (2C), 127.6, 128.7 (2C), 136.7, 138.6, 148.9, 
149.3. 
MS (FAB): m/z (%) = 410 (40) [M + Na+], 176 (100). 
HRMS–FAB: m/z [M + Na]+ calcd for 





Bromoenyne 11b (124 mg, 0.227 mmol) was 
converted to 12b (67.6 mg, 64% yield) and minor 
product (17.1 mg, 16% yield) by the reaction for 2.5 h. 
12b: Colorless oil; [α]23D +50.6 (c 0.60, CHCl3). 
IR (KBr): 3525 (OH), 1599 (naphthalene), 1340 
(NHSO2), 1161 cm–1 (NHSO2). 
1H NMR (500 MHz, CDCl3): δ = 0.86–1.94 (m, 11H), 
1.76 (s, 3H, CMe), 1.96 (s, 3H, CMe), 2.12 (s, 3H, 
PhMe), 4.62 (d, J = 16.5 Hz, 1H, NCHH), 4.75 (d, J = 
16.5 Hz, 1H, NCHH), 6.08 (d, J = 1.5 Hz, 1H, 1-H), 
7.00 (d, J = 7.9 Hz, 2H, Ph), 7.35–7.40 (m, 3H, Ar), 
7.64–7.70 (m, 3H, Ar), 8.14 (d, J = 8.5 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 21.3, 26.27, 26.30, 
26.8 (2C), 31.5, 32.3, 33.7, 47.3, 53.5, 72.2, 75.1, 
120.2, 124.6, 124.7, 126.4 (2C), 127.5, 128.8 (2C), 
129.1, 130.1, 134.3, 135.1, 136.5, 137.4, 138.0, 143.0. 
MS (FAB): m/z (%) = 464 (38) [M + H+], 380 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C28H34NO3S: 
464.2259; found: 464.2270. 
Minor product: colorless crystals; Mp 152–154 °C (n-
hexane–EtOAc); [α]23D +280 (c 0.33, CHCl3). 
IR (KBr): 3523 (OH), 1344 (NHSO2), 1166 cm–1 
(NHSO2). 
1H NMR (500 MHz, CDCl3): δ = 0.86–1.98 (m, 11H), 
1.00 (s, 3H, CMe), 1.20 (s, 3H, CMe), 2.41–2.43 (m, 
1H), 2.53 (s, 3H, PhMe), 4.36 (s, 1H), 4.41 (s, 1H), 
5.93 (s, 1H, C=CH), 6.66 (d, 2H, J = 7.3 Hz, Ar), 
7.13–7.35 (m, 5H, Ar), 7.66 (d, 2H, J = 8.5 Hz, Ph). 
13C NMR (67.8 MHz, CDCl3): δ = 21.8, 26.2, 26.35, 
26.42, 27.8, 29.0, 29.1, 29.2, 43.1, 49.4, 67.3, 70.6, 
114.0, 127.2, 127.4 (2C), 128.0 (2C), 128.2 (2C), 
129.4 (2C), 133.2, 137.1, 138.5, 143.3, 148.5, 149.1. 
MS (FAB): m/z (%) = 464 (56) [M + Na+], 154 (100). 
HRMS–FAB: m/z [M + Na]+ calcd for 
C28H33NNaO3S: 486.2074; found: 486.2079. 
Anal. Calcd for C28H33NO3S: C, 72.54; H, 7.17; N, 





Bromoenyne 11c (130 mg, 0.240 mmol) was 
converted to 12c (87.8 mg, 79% yield) by the reaction 
for 6 h. 
Colorless oil; IR (KBr): 1346 (NSO2), 1163 cm–1 
(NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.90–2.16 (m, 18H), 
2.38 (s, 3H, PhMe), 2.81–2.91 (m, 1H, 1’-CHH), 
2.95–3.05 (m, 1H, 1’-CHH), 4.71 (d, J = 16.2 Hz, 1H, 
3-CHH), 4.83 (d, J = 16.2 Hz, 1H, 3-CHH), 5.12 (s, 
1H, 1-H), 6.99 (d, J = 8.1 Hz, 2H, Ph), 7.34–7.46 (m, 
3H, Ar), 7.57 (d, J = 8.1 Hz, 2H, Ph), 7.70 (d, J = 7.5 
Hz, 1H, Ar), 7.92 (d, J = 8.1 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 14.0, 21.3, 23.2, 26.1, 
26.4, 26.5, 26.7, 29.5, 31.5, 32.9, 45.4, 54.9, 70.4, 
118.6, 124.0, 125.3, 125.4, 127.2 (2C), 128.5, 129.3 
(2C), 131.5, 132.6, 133.6, 135.1, 135.8, 136.8, 143.1. 
MS (FAB): m/z (%) = 462 (60) [M + H+], 378 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C29H36NO2S: 




Bromoenyne 11d (63.9 mg, 0.131 mmol) was 
converted to 12d (29.7 mg, 56% yield) by the reaction 
for 2 h. 
Colorless oil; IR (KBr): 1346 (NSO2), 1161 cm–1 
(NSO2). 
1H NMR (270 MHz, CDCl3): δ = 0.89–1.34 (m, 5H), 
1.50–1.75 (m, 6H), 2.24 (s, 3H, PhMe), 4.74 (d, J = 
15.5 Hz, 1H, 3-CHH), 4.78 (d, J = 15.5 Hz, 1H, 3-
CHH), 5.02 (d, J = 4.3 Hz, 1H, 1-H), 7.10 (d, J = 8.4 
Hz, 2H, Ph), 7.41–7.44 (m, 2H, Ar), 7.53 (d, J = 9.5 
Hz, 2H, Ar), 7.64 (d, J = 8.4 Hz, 2H, Ph), 7.71–7.79 
(m, 2H, Ar). 
13C NMR (68 MHz, CDCl3): δ = 21.5, 26.2, 26.3, 26.5, 
28.2, 28.8, 45.9, 53.8, 70.6, 120.4, 121.8, 125.7, 125.8, 
127.0 (2C), 127.5, 127.9, 129.4 (2C), 132.6, 132.8, 
135.2, 135.8, 137.9, 143.1. 
MS (FAB): m/z (%) = 406 (70) [M + H+], 322 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C25H28NO2S: 




Bromoenyne 11f (64.0 mg, 0.114 mmol) was 
converted to 12f (15.0 mg, 27% yield) by the reaction 
for 6 h. 
Colorless oil; [α]25D –46.5 (c 0.60, CHCl3). 
IR (KBr): 1346 (NSO2), 1163 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.83–1.05 (m, 6H), 
1.22–1.64 (m, 5H), 2.25 (s, 3H, PhMe), 4.75 (d, J = 
16.5 Hz, 1H, 3-CHH), 4.93 (d, J = 16.5 Hz, 1H, 3-
CHH), 5.02 (d, J = 2.4 Hz, 1H, 1-H), 6.94–6.97 (m, 
1H, Ar), 7.13 (d, J = 8.4 Hz, 2H, Ph), 7.28–7.74 (m, 
2H, Ar), 7.41 (dd, J = 8.1, 8.1 Hz, 1H, Ar), 7.48–7.51 
(m, 5H, Ar), 7.66 (d, J = 8.4 Hz, 2H, Ph), 7.76 (d, J = 
8.1 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 21.4, 26.1, 26.2, 26.5 
(2C), 31.2, 43.7, 55.0, 70.5, 119.9, 125.65, 125.70, 
125.9, 127.3 (2C), 127.8 (2C), 128.2, 128.6, 129.1, 
129.5 (2C), 130.5, 132.0, 133.3, 134.1, 135.1, 135.8, 
137.3, 137.6, 143.4. 
MS (FAB): m/z (%) = 482 (6.8) [M + H+], 154 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C31H32NO2S: 




Bromoenyne 11g (36.8 mg, 0.0897 mmol) was 
converted to 12g (13.7 mg, 46% yield) by the reaction 
for 6 h. 
Colorless oil; IR (KBr): 1346 (NSO2), 1161 cm–1 
(NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.99–1.33 (m, 6H), 
1.61–1.80 (m, 5H), 2.60 (s, 3H, SO2Me), 4.76 (d, J = 
16.2 Hz, 1H, 3-CHH), 4.86 (d, J = 16.2 Hz, 1H, 3-
CHH), 4.92 (d, J = 4.5 Hz, 1H, 1-H), 7.48–7.51 (m, 
2H, Ar), 7.71 (s, 2H, 4-H and 9-H), 7.82–7.87 (m, 2H, 
Ar). 
13C NMR (75 MHz, CDCl3): δ = 26.1, 26.17, 26.21, 
28.5, 28.6, 34.8, 45.3, 53.8, 70.4, 120.9, 122.3, 126.2, 
126.3, 127.8, 128.0, 132.9, 133.2, 135.9, 138.2. 
MS (FAB): m/z (%) = 330 (34) [M + H+], 246 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C19H24NO2S: 




Bromoenyne 11i (72.0 mg, 0.136 mmol) was 
converted to 12i (39.9 mg, 65% yield) by the reaction 
for 3 h. 
Colorless oil; IR (KBr): 1346 (NSO2), 1161 cm–1 
(NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.82 (t, J = 7.2 Hz, 
3H, CMe), 0.97 (t, J = 7.2 Hz, 3H, CMe), 1.15–1.28 
(m, 5H), 1.39–1.54 (m, 5H), 1.74–1.85 (m, 1H), 1.98–
2.10 (m, 1H), 2.24 (s, 3H, PhMe), 2.88 (dt, J = 13.8, 
3.3 Hz, 1H, 1’-CHH), 2.98 (dt, J = 13.8, 3.3 Hz, 1H, 
1’-CHH), 4.78 (d, J = 16.5 Hz, 1H, 3-CHH), 4.84 (d, J 
= 16.5 Hz, 1H, 3-CHH), 5.29 (dd, J = 5.7, 3.3 Hz, 1H, 
1-H), 7.09 (d, J = 8.7 Hz, 2H, Ph), 7.39–7.47 (m, 3H, 
Ar), 7.64 (d, J = 8.7 Hz, 2H, Ph), 7.73 (dd, J = 7.8, 1.8 
Hz, 1H, Ar), 7.93 (dd, J = 7.5, 1.8 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 14.0, 14.1, 21.3, 22.5, 
23.3, 24.1, 29.2, 31.8, 32.8, 36.4, 53.3, 65.4, 119.1, 
123.9, 125.4, 125.5, 127.0 (2C), 128.5, 129.5 (2C), 
131.5, 132.5, 133.7, 135.2, 135.6, 137.1, 143.2. 
MS (FAB): m/z (%) = 450 (62) [M + H+], 378 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C28H36NO2S: 




Bromoenyne 11k (94.2 mg, 0.199 mmol) was 
converted to 12k (37.8 mg, 48% yield) by the reaction 
for 1.5 h. 
Colorless oil; IR (KBr): 1346 (NSO2), 1163 cm–1 
(NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.81 (t, J = 6.9 Hz, 
3H, CMe), 1.02–1.10 (m, 1H), 1.18–1.25 (m, 4H), 
1.39–1.47 (m, 1H), 1.89–2.00 (m, 1H), 2.13–2.25 (m, 
1H), 2.31 (s, 3H, PhMe), 4.77 (d, J = 14.7 Hz, 1H, 3-
CHH), 4.83 (d, J = 14.7 Hz, 1H, 3-CHH), 5.16 (t, J = 
4.5 Hz, 1H, 1-H), 7.20 (d, J = 8.1 Hz, 2H, Ph), 7.40–
7.46 (m, 2H, Ar), 7.53 (s, 1H, Ar), 7.57 (s, 1H, Ar), 
7.72 (d, J = 8.1 Hz, 2H, Ph), 7.75–7.79 (m, 2H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 14.0, 21.4, 22.5, 23.2, 
31.8, 37.0, 53.4, 65.5, 120.8, 120.9, 125.88, 125.93, 
127.3 (2C), 127.67, 127.68, 127.8, 129.7 (2C), 133.0, 




Bromoenyne 11l (52.8 mg, 0.118 mmol) was 
converted to 12l (10.5 mg, 24% yield) by the reaction 
for 4 h. 
Colorless oil; [α]27D –20.8 (c 0.60, CHCl3). 
IR (KBr): 1344 (NSO2), 1161 cm–1 (NSO2). 
1H NMR (500 MHz, CDCl3): δ = 0.80 (d, J = 6.7 Hz, 
3H, CMe), 0.99 (d, J = 7.3 Hz, 3H, CMe), 2.19 (s, 3H, 
PhMe), 2.32–2.36 (m, 1H, Me2CH), 4.71 (s, 1H, J = 
15.5 Hz, 3-CHH), 4.74 (d, J = 15.5 Hz, 1H, 3-CHH), 
4.99 (d, J = 4.3 Hz, 1H, 1-H), 7.06 (d, J = 7.9 Hz, 2H, 
Ph), 7.357 (d, J = 6.1 Hz, 1H, Ar), 7.365 (d, J = 6.1 
Hz, 1H, Ar), 7.47 (s, 1H, Ar), 7.50 (s, 1H, Ar), 7.59 (d, 
J = 7.9 Hz, 2H, Ph), 7.66–7.71 (m, 2H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 17.3, 18.4, 21.4, 35.8, 
53.8, 70.9, 120.6, 121.9, 125.8, 125.9, 127.1 (2C), 
127.6, 128.0, 129.6 (2C), 132.8, 133.0, 135.3, 135.9, 
137.6, 143.3. 
MS (FAB): m/z (%) = 366 (22) [M + H+], 154 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C22H24NO2S: 





Bromoenyne 11o (57.3 mg, 0.0818 mmol) was 
converted to 12o (20.0 mg, 39% yield) by the reaction 
using Pd(OAc)2 (0.8 mg, 0.00327 mmol) for 24 h. 
Colorless oil; [α]23D –86.5 (c 0.60, CHCl3). 
IR (KBr): 1346 (NSO2), 1161 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.63 (s, 9H, CMe3), 
1.26 (d, J = 6.0 Hz, 3H, CMe), 2.17 (s, 3H, CMe), 
2.32 (s, 3H, PhMe), 4.27 (d, J = 6.0 Hz, 1H, OCH), 
4.81 (d, J = 15.6 Hz, 1H, 3-CHH), 5.00 (d, J = 15.6 
Hz, 1H, 3-CHH), 5.13 (s, 1H, 1-H), 6.99–7.02 (m, 6H, 
Ar), 7.27–7.58 (m, 11H, Ar), 7.75 (d, J = 7.5 Hz, 1H, 
Ar), 7.90 (d, J = 8.1 Hz, 1H, Ar). 
13C NMR (68 MHz, CDCl3): δ = 15.5, 18.8, 21.4, 21.6, 
26.6 (3C), 55.0, 70.8, 72.8, 118.7, 123.7, 125.3 (2C), 
127.0 (2C), 127.23 (2C), 127.25 (2C), 127.6, 128.2, 
129.2 (2C), 129.37, 129.40, 132.1, 132.7, 133.4, 134.1, 
135.0, 135.5 (2C), 135.9 (2C), 136.2, 136.8, 143.1. 
MS (FAB): m/z (%) = 620 (21) [M + H+], 336 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C38H42NO3SSi: 





Bromoenyne 11p (60.2 mg, 0.105 mmol) was 
converted to 12p (29.4 mg, 57% yield) by the reaction 
for 5 h. 
Colorless oil; [α]26D –63.9 (c 0.82, CHCl3). 
IR (KBr): 1348 (NSO2), 1163 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.97 (t, J = 7.2 Hz, 
3H, CMe), 1.11–1.46 (m, 9H), 1.60–1.94 (m, 6H), 
2.20 (s, 3H, PhMe), 2.82 (dt, J = 11.7, 4.8 Hz, 1H, 1’-
CHH), 3.40 (dt, J = 11.7, 5.1 Hz, 1H, 1’-CHH), 3.91 
(s, 3H, OMe), 4.70 (d, J = 16.5 Hz, 1H, NCHH), 4.79 
(d, J = 16.5 Hz, 1H, NCHH), 5.10 (s, 1H, 1-H), 6.77 
(dd, J = 5.7, 3.3 Hz, 1H, 7-H), 7.01 (d, J = 8.4 Hz, 2H, 
Ph), 7.26–7.28 (m, 3H, Ar), 7.57 (d, J = 8.4 Hz, 2H, 
Ph). 
13C NMR (75 MHz, CDCl3): δ = 14.2, 21.3, 23.5, 26.2, 
26.5, 26.6, 26.7, 31.5, 33.3, 34.5, 45.7, 55.0, 55.2, 
70.8, 105.2, 118.6, 121.3, 123.9, 125.4, 127.2 (2C), 
129.4 (2C), 134.1, 135.2, 136.0, 136.4, 137.7, 143.1, 
157.7. 
MS (FAB): m/z (%) = 492 (38) [M + H+], 408 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C30H38NO3S: 





Bromoenyne 11q (57.6 mg, 0.101 mmol) was 
converted to 12q (18.5 mg, 37% yield) by the reaction 
for 8 h. 
Colorless oil; [α]28D –88.2 (c 0.40, CHCl3). 
IR (KBr): 1344 (NSO2), 1163 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 1.00 (t, J = 6.9 Hz, 
3H, CMe), 1.10–1.92 (m, 15H), 2.19 (s, 3H, PhMe), 
2.81–2.95 (m, 2H, 1’-CH2), 3.91 (s, 3H, OMe), 4.68 
(d, J = 16.2 Hz, 1H, NCHH), 4.78 (d, J = 16.2 Hz, 1H, 
NCHH), 5.11 (s, 1H, 1-H), 7.01 (d, J = 8.1 Hz, 2H, 
Ph), 7.09 (dd, J = 9.0, 3.0 Hz, 1H, 6-H), 7.20 (d, J = 
3.0 Hz, 1H, 8-H), 7.27 (s, 1H, 4-H), 7.59 (d, J = 8.1 
Hz, 2H, Ph), 7.61 (d, J = 9.0 Hz, 1H, 5-H). 
13C NMR (75 MHz, CDCl3): δ = 14.0, 21.3, 23.3, 26.2, 
26.5 (2C), 26.7, 29.5, 31.6, 32.3, 45.5, 54.8, 55.3, 70.5, 
103.1, 117.4, 118.4, 127.2 (2C), 129.0, 129.3 (2C), 
129.9, 131.1, 132.6, 133.6, 135.2, 137.4, 143.1, 157.4. 
MS (FAB): m/z (%) = 492 (30) [M + H+], 408 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C30H38NO3S: 





Bromoenyne 11j (61.3 mg, 0.119 mmol) was 
converted to 13j (3.6 mg, 7% yield) by the reaction 
for 7 h. 
Colorless oil; IR (KBr): 1348 (NSO2), 1163 cm–1 
(NSO2). 
1H NMR (500 MHz, CDCl3): δ = 0.93 (t, J = 7.5 Hz, 
3H, CMe), 0.97 (s, 9H, CMe3), 1.25–1.37 (m, 4H), 
1.89–2.04 (m, 2H), 2.37 (s, 3H, PhMe), 4.24 (s, 1H, 2-
H), 4.35 (dd, J = 17.1, 1.8 Hz, 1H, 5-CHH), 4.58 (dd, 
J = 17.1, 2.4 Hz, 1H, 5-CHH), 5.60 (dd, J = 9.2, 5.5 
Hz, 1H, C=CH), 6.48 (s, 1H, C=CH), 7.19–7.21 (m, 
4H, Ph), 7.23 (d, J = 7.3 Hz, 1H, Ph), 7.34 (d, J = 7.3 
Hz, 1H, Ph), 7.36 (d, J = 7.9 Hz, 1H, Ph), 7.63 (d, J = 
7.9 Hz, 2H, Ph). 
13C NMR (75 MHz, CDCl3): δ = 14.1, 21.5, 22.7, 27.3 
(3C), 31.0, 31.7, 38.2, 52.8, 69.6, 118.0, 125.5, 126.9, 
127.5 (2C), 128.4 (2C), 128.7 (2C), 129.5 (2C), 135.2, 
136.8, 137.4, 138.7, 143.2. 
MS (FAB): m/z (%) = 438 (15) [M + H+], 154 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C27H36NO2S: 




Bromoenyne 11m (43.7 mg, 0.105 mmol) was 
converted to 14m (19.2 mg, 54% yield) by the 
reaction for 0.5 h. 
Colorless oil; IR (KBr): 2362 (C≡C), 2330 (C≡C), 
1352 (NSO2), 1165 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 1.69 (t, J = 2.4 Hz, 
3H, CMe), 2.35 (s, 3H, PhMe), 4.13 (q, J = 2.4 Hz, 
2H, NCH2), 4.38 (s, 2H, NCH2), 7.16 (dd, J = 6.6, 1.8 
Hz, 2H, Ph), 7.23–7.30 (m, 5H, Ph), 7.75 (dd, J = 6.6, 
1.8 Hz, 2H, Ph). 
13C NMR (75 MHz, CDCl3): δ = 3.46, 21.4, 37.0, 37.1, 
71.6, 81.6, 81.9, 85.6, 122.2, 128.0 (2C), 128.1 (2C), 




Bromoenyne 11n (59.2 mg, 0.152 mmol) was 
converted to 14n (12.0 mg, 26% yield) by the reaction 
for 2.5 h. 
Colorless oil; IR (KBr): 3317 (NH), 2237 cm–1 (C≡C). 
1H NMR (300 MHz, CDCl3): δ = 0.92 (t, J = 7.5 Hz, 
3H, CMe), 1.13–1.55 (m, 10H), 1.65–1.85 (m, 5H), 
2.22 (td, J = 6.9, 1.8 Hz, 2H, CH2C≡C), 3.42 (dt, J = 
5.1, 1.8 Hz, 1H, NCH), 3.68 (d, J = 16.8 Hz, 1H, 
NCHH), 3.84 (d, J = 16.8 Hz, 1H, NCHH), 7.28–7.30 
(m, 3H, Ph), 7.39–7.44 (m, 2H, Ph). 
13C NMR (75 MHz, CDCl3): δ = 13.6, 18.4, 22.0, 26.1, 
26.2, 26.5, 28.4, 30.2, 31.1, 37.2, 42.5, 55.0, 79.2, 





Bromoenyne 15a (58.2 mg, 0.109 mmol) was 
converted to 16a (21.3 mg, 43% yield) by the reaction 
for 2 h. 
Colorless oil; [α]29D –67.2 (c 1.02, CHCl3). 
IR (KBr): 1344 (NSO2), 1163 cm–1 (NSO2). 
1H NMR (270 MHz, CDCl3): δ = 0.94 (t, J = 7.3 Hz, 
3H, CMe), 1.00–1.89 (m, 16H), 2.23 (s, 3H, PhMe), 
2.71 (t, J = 6.8 Hz, 2H, 1’-CH2), 4.63 (d, J = 15.9 Hz, 
1H, 7-CHH), 4.72 (d, J = 15.9 Hz, 1H, 7-CHH), 5.02 
(s, 1H, 5-H), 6.68 (d, J = 2.2 Hz, 1H, 2-H), 6.97 (s, 1H, 
8-H), 7.03 (d, J = 8.4 Hz, 2H, Ph), 7.52 (d, J = 2.2 Hz, 
1H, 3-H), 7.56 (d, J = 8.4 Hz, 2H, Ph). 
13C NMR (68 MHz, CDCl3): δ = 14.1, 21.4, 23.0, 26.3, 
26.5, 26.6, 26.8, 30.5, 31.6, 32.7, 45.6, 55.1, 70.0, 
102.4, 105.3, 126.7, 127.1 (2C), 129.2 (2C), 129.5, 
132.7, 134.5, 135.1, 143.0, 144.5, 154.7. 
MS (FAB): m/z (%) = 452 (45) [M + H+], 368 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C27H34NO3S: 





Bromoenyne 15b (111 mg, 0.162 mmol) was 
converted to 16b (73.3 mg, 75%) by the reaction 
using Pd(OAc)2 (7.7 mg, 0.0346 mmol) in DMF at 
120 °C for 2 h. 
Colorless oil; [α]26D +79.7 (c 0.98, CHCl3). 
IR (KBr): 1597 (NC=C), 1360 (NSO2), 1346 (NSO2), 
1178 (NSO2), 1161 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.92 (t, J = 7.1 Hz, 
3H, CMe), 1.01–1.37 (m, 8H), 1.61–1.85 (m, 7H), 
2.20 (s, 3H, PhMe), 2.38 (s, 3H, PhMe), 2.61–2.67 (m, 
2H, 1’-CH2), 4.63 (d, J = 15.9 Hz, 1H, 7-CHH), 4.76 
(d, J = 15.9 Hz, 1H, 7-CHH), 4.97 (s, 1H, 5-H), 6.57 
(dd, J = 3.8, 0.7 Hz, 1H, 3-H), 6.97 (d, J = 7.9 Hz, 2H, 
Ph), 7.25 (d, J = 7.9 Hz, 2H, Ph), 7.46 (d, J = 3.8 Hz, 
1H, 2-H), 7.48 (s, 1H, 8-H), 7.53 (ddd, J = 7.9, 1.8, 
1.8 Hz, 2H, Ph), 7.73 (ddd, J = 7.9, 1.8, 1.8 Hz, 2H, 
Ph). 
13C NMR (126 MHz, CDCl3): δ = 14.0, 21.3, 21.6, 
22.9, 26.2, 26.4, 26.5, 26.7, 30.1, 31.5, 32.6, 45.4, 
55.2, 69.9, 104.5, 107.2, 125.8, 126.8 (2C), 127.2 
(2C), 129.3 (3C), 129.6, 129.9, 130.0, 133.5, 134.7, 
135.1, 135.2, 135.4, 143.0, 145.0. 
MS (FAB): m/z (%) = 605 (5.2) [M + H+], 521 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C34H41N2O4S2: 






Bromoenyne 15c (72.0 mg, 0.101 mmol) was 
converted to 16c (51.4 mg, 81%) by the reaction using 
Pd(OAc)2 (4.5 mg, 0.0202 mmol) in DMF at 120 °C 
for 2 h. 
Colorless oil; [α]26D +52.2 (c 1.645, CHCl3). 
IR (KBr): 1603 (NC=C), 1350 (NSO2), 1161 cm–1 
(NSO2). 
1H NMR (270 MHz, CDCl3): δ = 0.86 (t, J = 6.9 Hz, 
3H, CMe), 0.91–1.34 (m, 8H), 1.40–1.86 (m, 7H), 
2.23 (s, 3H, PhMe), 2.32 (s, 3H, PhMe), 2.46 (s, 6H, 
PhMe), 2.68 (t, J = 6.6 Hz, 2H, 1’-CH2), 4.54 (d, J = 
16.0 Hz, 1H, 7-CHH), 4.66 (d, J = 16.0 Hz, 1H, 7-
CHH), 4.96 (s, 1H, 5-H), 6.53 (d, J = 3.7 Hz, 1H, 3-H), 
6.94–6.99 (m, 5H, Ar), 7.39 (d, J = 3.7 Hz, 1H, 2-H), 
7.50 (d, J = 8.1 Hz, 2H, Ph). 
13C NMR (126 MHz, CDCl3): δ = 14.0, 21.0, 21.3, 
22.5 (2C), 22.9, 26.2, 26.5, 26.7, 30.1, 31.5, 32.7, 45.3, 
55.2, 69.9, 103.7, 105.2 (2C), 125.9, 127.2 (2C), 
129.2 (3C), 129.3, 129.6, 132.3 (3C), 132.9, 134.6, 
134.7, 135.1, 140.1, 143.0, 144.1. 
MS (FAB): m/z (%) = 633 (28) [M + H+], 549 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C36H45N2O4S2: 





Bromoenyne 15d (49.7 mg, 0.0778 mmol) was 
converted to 16d (22.7 mg, 52%) by the reaction 
using Pd(OAc)2 (1.8 mg, 0.00802 mmol) for 12 h. 
Pale orange oil; [α]25D +37.8 (c 0.740, CHCl3). 
IR (KBr): 1599 (NC=C), 1387 (NSO2), 1344 (NSO2), 
1159 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.96 (t, J = 7.1 Hz, 
3H, CMe), 1.03–1.54 (m, 9H), 1.61–1.94 (m, 6H), 
2.23 (s, 3H, PhMe), 2.71–2.79 (m, 2H, 1’-CH2), 2.785 
(s, 3H, NMe), 2.787 (s, 3H, NMe), 4.63 (d, J = 16.0 
Hz, 1H, 7-CHH), 4.73 (d, J = 16.0 Hz, 1H, 7-CHH), 
5.07 (s, 1H, 5-H), 6.57 (d, J = 3.7 Hz, 1H, 3-H), 7.04 
(d, J = 8.3 Hz, 2H, Ph), 7.36 (d, J = 3.7 Hz, 1H, 2-H), 
7.42 (s, 1H, 8-H), 7.57 (d, J = 8.3 Hz, 2H, Ph). 
13C NMR (75 MHz, CDCl3): δ = 14.0, 21.3, 22.9, 26.2, 
26.4, 26.5, 26.7, 30.1, 31.5, 32.6, 38.4 (2C), 45.4, 55.1, 
70.0, 104.6, 105.1, 126.6, 127.2 (2C), 129.2, 129.26 
(2C), 129.29, 132.9, 134.6, 135.1, 135.3, 143.0. 
MS (FAB): m/z (%) = 558 (37) [M + H+], 474 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C29H40N3O4S2: 





Bromoenyne 15e (53.5 mg, 0.0780 mmol) was 
converted to 16e (20.0 mg, 42%) by the reaction using 
Pd(OAc)2 (3.5 mg, 0.0156 mmol) in DMF at 120 °C 
for 4 h. 
Colorless oil; [α]26D –349.8 (c 0.86, CHCl3). 
IR (KBr): 1597 (NC=C), 1369 (NSO2), 1344 (NSO2), 
1174 (NSO2), 1161 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.83–1.47 (m, 11H), 
1.51–1.62 (m, 5H), 1.79–1.85 (m, 2H), 2.25 (s, 3H, 
PhMe), 2.30 (s, 3H, PhMe), 2.38–2.53 (m, 1H, 1’-
CHH), 3.49–3.59 (m, 1H, 1’-CHH), 4.54 (d, J = 15.9 
Hz, 1H, 5-CHH), 4.69 (dd, J = 15.9, 0.6 Hz, 1H, 5-
CHH), 4.95 (s, 1H, 7-H), 6.52 (d, J = 3.8 Hz, 1H, 3-H), 
6.91 (s, 1H, 4-H), 7.04 (d, J = 8.1 Hz, 2H, Ph), 7.08 (d, 
J = 8.1 Hz, 2H, Ph), 7.37 (ddd, J = 8.1, 1.9, 1.9 Hz, 
2H, Ph), 7.56 (ddd, J = 8.1, 1.9, 1.9 Hz, 2H, Ph), 7.59 
(d, J = 3.8 Hz, 1H, 2-H). 
13C NMR (126 MHz, CDCl3): δ = 14.0, 21.4, 21.5, 
22.9, 26.2, 26.6 (2C), 26.7, 30.6, 31.0, 32.1, 45.7, 55.0, 
70.5, 111.1, 111.9, 126.48, 126.49 (2C), 127.2 (2C), 
129.3 (2C), 129.4 (2C), 132.1, 133.9, 134.2, 134.4, 
135.1, 135.3, 137.2, 143.2, 144.6. 
MS (FAB): m/z (%) = 605 (31) [M + H+], 521 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C34H41N2O4S2: 





Bromoenyne 17a (74.0 mg, 0.101 mmol) was 
converted to 18a (33.8 mg, 51% yield) by the reaction 
using Pd(OAc)2 (2.3 mg, 0.0101 mmol) in DMF at 
120 °C for 18 h. 
Colorless oil; [α]26D –122 (c 0.30, CHCl3). 
IR (KBr): 1597 (C=CN), 1367 (NSO2), 1346 (NSO2), 
1173 (NSO2), 1163 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.88 (t, J = 7.2 Hz, 
3H, CMe), 1.11–1.30 (m, 9H), 1.53–1.93 (m, 6H), 
2.17 (s, 3H, PhMe), 2.22 (s, 3H, PhMe), 2.63–2.73 (m, 
1H, 1’-CHH), 3.84–3.94 (m, 1H, 1’-CHH), 4.61 (d, J 
= 16.5 Hz, 1H, 1-CHH), 4.76 (d, J = 16.5 Hz, 1H, 1-
CHH), 5.07 (s, 1H, 3-H), 6.72 (d, J = 8.4 Hz, 2H, Ph), 
6.78 (d, J = 8.4 Hz, 2H, Ph), 7.06 (d, J = 8.1 Hz, 2H, 
Ph), 7.12 (s, 1H, 10-H), 7.25–7.30 (m, 1H, Ar), 7.40 
(dd, J = 7.5, 7.5, 1.5 Hz, 1H, Ar), 7.47 (dd, J = 7.5, 0.6 
Hz, 1H, Ar), 7.61 (d, J = 8.4 Hz, 2H, Ph), 8.16 (d, J = 
7.5 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 14.0, 21.4, 21.5, 22.9, 
26.3, 26.5, 26.6, 26.7, 31.0, 31.15, 31.20, 45.9, 55.3, 
71.0, 110.4, 119.2, 120.6, 125.8, 127.0 (2C), 127.1, 
127.3 (2C), 128.3 (2C), 129.5 (2C), 130.0, 131.08, 
131.13, 131.9, 135.0, 135.8, 140.17, 140.24, 142.5, 
143.4, 144.3. 
MS (FAB): m/z (%) = 655 (10) [M + H+], 154 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C38H43N2O4S2: 






Bromoenyne 17b (53.1 mg, 0.0695 mmol) was 
converted to 18b (14.9 mg, 31%) by the reaction 
using Pd(OAc)2 (0.8 mg, 0.00356 mmol) in DMF at 
120 °C for 3 h.  
Pale yellow oil; [α]26D –107.6 (c 0.690, CHCl3). 
IR (KBr): 1601 (NC=C), 1346 (NSO2), 1162 cm–1 
(NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.92 (t, J = 7.1 Hz, 
3H, CMe), 1.01–1.37 (m, 8H), 1.61–1.85 (m, 7H), 
2.11 (s, 6H, PhMe), 2.20 (s, 3H, PhMe), 2.38 (s, 3H, 
PhMe), 2.64 (dt, J = 14.6, 5.0 Hz, 1H, 1’-CHH), 3.55 
(dt, J = 14.6, 5.0 Hz, 1H, 1’-CHH), 4.67 (d, J = 15.6 
Hz, 1H, 1-CHH), 4.80 (d, J = 15.6 Hz, 1H, 1-CHH), 
5.01 (s, 1H, 3-H), 6.67 (s, 2H, Ph), 7.03 (d, J = 7.9 Hz, 
2H, Ph), 7.15–7.20 (m, 2H, Ar), 7.35 (s, 1H, 10-H), 
7.56–7.59 (m, 1H, Ar), 7.58 (d, J = 7.9 Hz, 2H, Ph), 
7.66–7.67 (m, 1H, Ar). 
13C NMR (126 MHz, CDCl3): δ = 14.0, 20.9, 21.4, 
22.5 (2C), 22.9, 26.2, 26.4, 26.6, 26.8, 31.1, 31.2, 31.4, 
45.6, 55.3, 71.0, 110.4, 116.7, 119.4 (2C), 124.1, 
126.5, 127.1, 127.2 (2C), 128.7, 129.1, 129.5 (2C), 
131.8 (2C), 134.1, 134.6, 135.0, 139.9 (2C), 140.1, 
141.1, 143.1, 143.3. 
MS (FAB): m/z (%) = 683 (16) [M + H+], 154 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C40H47N2O4S2: 





Bromoenyne 17d (118 mg, 0.20 mmol) was converted 
to 18d (43.7 mg, 43%) by the reaction using 
Pd(OAc)2 (4.5 mg, 0.0198 mmol) for 36 h. 
Pale yellow oil; [α]27D +10.2 (c 1.28, CHCl3). 
IR (KBr): 1601 (NC=C), 1342 (NSO2), 1161 (NSO2), 
1092 cm–1 (NC). 
1H NMR (300 MHz, CDCl3): δ = 0.96–1.00 (m, 4H), 
1.04–1.48 (m, 8H), 1.60–1.64 (m, 2H), 1.77–1.92 (m, 
4H), 2.19 (s, 3H, PhMe), 2.73–2.82 (m, 1H, 1’-CHH), 
3.12–3.19 (m, 1H, 1’-CHH), 3.98 (s, 3H, NMe), 4.74 
(d, 1H, J = 15.4 Hz, 1-CHH), 4.83 (d, 1H, J = 15.4 Hz, 
1-CHH), 5.06 (s, 1H, 3-H), 7.01 (d, J = 7.9 Hz, 2H, 
Ph), 7.18 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 7.34 (d, J = 8.0 
Hz, 1H, Ar), 7.43 (dd, J = 8.0, 8.0 Hz, 1H, Ar), 7.58 (s, 
1H, 10-H), 7.58 (d, J = 7.9 Hz, 2H, Ph), 7.94 (d, J = 
8.0 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 14.8, 22.1, 23.6, 27.0, 
27.2, 27.3, 27.5, 29.9, 32.3, 32.8, 34.9, 46.7, 56.0, 
71.5, 109.5, 111.6, 119.8, 120.3, 120.8, 123.2, 125.1, 
126.5, 127.9 (2C), 129.6, 130.1 (2C), 136.0, 138.4, 
139.8, 143.1, 143.8. 
MS (FAB): m/z (%) = 515 (21) [M + H+], 431 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C32H39N2O2S: 





Bromoenyne 17e (70.4 mg, 0.118 mmol) was 
converted to 18e (29.7 mg, 49% yield) by the reaction 
for 3 h. 
Colorless oil; [α]25D +27.8 (c 0.40, CHCl3). 
IR (KBr): 1344 (NSO2), 1161 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.99 (t, J = 7.2 Hz, 
3H, CMe), 1.05–1.92 (m, 15H), 2.20 (s, 3H, PhMe), 
2.72–2.86 (m, 2H, 1’-CH2), 4.72 (d, J = 15.9 Hz, 1H, 
1-CHH), 4.83 (d, J = 15.9 Hz, 1H, 1-CHH), 5.09 (s, 
1H, 3-H), 7.03 (d, J = 8.1 Hz, 2H, Ph), 7.40–7.43 (m, 
2H, Ar), 7.59 (d, J = 8.1 Hz, 2H, Ph), 7.65 (s, 1H, Ar), 
7.79–7.83 (m, 1H, Ar), 8.00–8.03 (m, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 14.0, 21.3, 23.0, 26.2, 
26.4, 26.5, 26.7, 30.7, 31.6, 32.2, 45.4, 55.1, 70.4, 
112.3, 121.4, 122.8, 124.4, 126.7, 127.2 (2C), 129.4 
(2C), 131.2, 135.0, 135.3, 135.5, 135.6, 137.3, 139.1, 
139.3, 143.3. 
MS (FAB): m/z (%) = 518 (23) [M + H+], 154 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C31H36NO2S2: 





Bromoenyne 17f (62.0 mg, 0.106 mmol) was 
converted to 18f (31.4 mg, 59% yield) by the reaction 
for 1 h. 
Colorless oil; [α]26D –119 (c 0.35, CHCl3). 
IR (KBr): 1346 (NSO2), 1163 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 1.00 (t, J = 6.9 Hz, 
3H, CMe), 1.15–1.93 (m, 15H), 2.19 (s, 3H, PhMe), 
2.89 (dt, J = 14.1, 6.3 Hz, 1H, 1’-CHH), 3.04 (dt, J = 
9.0, 5.4 Hz, 1H, 1’-CHH), 4.69 (d, J = 16.5 Hz, 1H, 1-
CHH), 4.80 (d, J = 16.5, 1H, 1-CHH), 5.09 (s, 1H, 3-
H), 7.03 (d, J = 8.1 Hz, 2H, Ph), 7.06 (s, 1H, Ar), 7.33 
(ddd, J = 7.5, 7.5, 0.9 Hz, 1H, Ar), 7.42 (ddd, J = 7.5, 
7.5, 0.9 Hz, 1H, Ar), 7.52 (d, J = 7.5 Hz, 1H, Ar), 7.59 
(d, J = 8.1 Hz, 2H, Ph), 7.84 (d, J = 7.5 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 14.0, 21.3, 23.2, 26.2, 
26.4, 26.5, 26.7, 30.6, 31.6 (2C), 45.7, 55.4, 70.1, 
102.7, 111.6, 122.1, 122.2, 122.8, 123.9, 126.5, 127.2 
(2C), 129.4 (2C), 132.5, 133.1, 135.1, 137.3, 143.2, 
156.3, 156.4. 
MS (FAB): m/z (%) = 502 (36) [M + H+], 418 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C31H36NO3S: 





Bromoenyne 17g (132 mg, 0.22 mmol) was converted 
to 18g (48.7 mg, 43%) by the reaction using Pd(OAc)2 
(1.0 mg, 0.0044 mmol) in DMF at 120 °C for 2 h and 
a further 3 h with additional Pd(OAc)2 (1.5 mg, 
0.0066 mmol). 
Colorless oil; [α]26D –165.5 (c 0.63, CHCl3). 
IR (KBr): 1344 (NSO2), 1161 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.95–1.02 (m, 4H), 
1.11–1.61 (m, 10H), 1.79–1.97 (m, 4H), 2.16 (s, 3H, 
PhMe), 3.09 (td, J = 12.7, 4.6 Hz, 1H, 1’-CHH), 3.58 
(td, J = 12.7, 4.6 Hz, 1H, 1’-CHH), 4.78 (d, J = 16.2 
Hz, 1H, 3-CHH), 4.90 (d, J = 16.2 Hz, 1H, 3-CHH), 
5.20 (s, 1H, 1-H), 7.00 (d, J = 8.1 Hz, 2H, Ph), 7.41 (s, 
1H, Ar), 7.54–7.64 (m, 6H, Ar), 7.86 (dd, J = 6.8, 2.2 
Hz, 1H, Ar), 8.74 (d, J = 7.8 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 13.9, 21.3, 23.1, 26.2, 
26.5, 26.7 (2C), 31.1, 31.5, 33.9, 45.6, 55.3, 71.4, 
120.1, 125.8, 125.9, 126.7, 127.2 (3C), 128.0, 128.9, 
129.0, 129.4 (2C), 131.1, 133.3, 134.1, 134.6, 135.1, 
135.9, 139.8, 143.2. 
MS (FAB): m/z (%) = 512 (49) [M + H+], 428 (100). 
HRMS–FAB: m/z [M + H]+ calcd for C33H38NO2S: 




Bromoenyne 19a (48.8 mg, 0.0993 mmol) was 
converted to 20a (28.1 mg, 68%) by the reaction using 
Pd(OAc)2 (1.1 mg, 0.0050 mmol) for 2 h. 
Colorless oil; IR (KBr): 1733 cm–1 (C=O). 
1H NMR (300 MHz, CDCl3): δ = 0.82 (t, J = 6.7 Hz, 
3H, CMe), 1.02 (t, J = 7.1 Hz, 3H, CMe), 1.13–1.82 
(m, 18H), 2.93–3.02 (m, 1H, 1’-CHH), 3.07–3.17 (m, 
1H, 1’-CHH), 3.45 (d, J = 16.7 Hz, 1H, 3-CHH), 
3.96–4.37 (m, 6H, 2 × OCH2, 1-H, and 3-CHH), 7.37 
(ddd, J = 8.0, 8.0, 1.1 Hz, 1H, Ar), 7.42 (ddd, J = 8.0, 
8.0, 1.1 Hz, 1H, Ar), 7.47 (s, 1H, 4-H), 7.73 (d, J = 8.0 
Hz, 1H, Ar), 7.97 (d, J = 8.0 Hz, 1H, Ar). 
13C NMR (75 MHz, CDCl3): δ = 13.9, 14.0 (2C), 14.1, 
22.5, 23.5, 26.9, 29.5, 31.8, 32.3, 32.8, 38.8, 48.2, 
61.45, 61.50, 65.4, 121.1, 123.9, 124.8, 124.9, 128.3, 
131.6, 133.6, 133.7, 137.4, 142.3, 170.0, 171.6. 
MS (FAB): m/z (%) = 461 (8.2) [M + Na+], 438 (100). 
HRMS–FAB: m/z [M + Na]+ calcd for C28H38NaO4: 





Bromoenyne 19b (104 mg, 0.157 mmol) was 
converted to 20b (31.9 mg, 35%) by the reaction 
using Pd(OAc)2 (1.8 mg, 0.00786 mmol) in DMF at 
120 °C for 24 h. 
Colorless oil; IR (KBr): 1732 (C=O), 1597 (NC=C), 
1373 (NSO2), 1176 cm–1 (NSO2). 
1H NMR (300 MHz, CDCl3): δ = 0.80 (t, J = 7.0 Hz, 
3H, CMe), 0.95 (t, J = 7.0 Hz, 3H, CMe), 1.13–1.73 
(m, 18H), 2.36 (s, 3H, PhMe), 2.76 (t, J = 7.9 Hz, 2H, 
1’-CH2), 3.37 (d, J = 16.7 Hz, 1H, 7-CHH), 3.91–4.37 
(m, 6H, 2 × OCH2, 5-H, and 7-CHH), 6.61 (d, J = 3.8 
Hz, 1H, 3-H), 7.24 (d, J = 8.3 Hz, 2H, Ph), 7.46 (d, J 
= 3.8 Hz, 1H, 2-H), 7.58 (s, 1H, 8-H), 7.77 (d, J = 8.3 
Hz, 2H, Ph). 
13C NMR (75 MHz, CDCl3): δ = 13.9, 13.96, 13.99, 
14.1, 21.6, 22.4, 23.3, 26.8, 30.2, 31.8, 32.3, 32.7, 
39.0, 47.4, 61.4, 61.5, 65.6, 107.0, 107.4, 125.0, 126.9 
(2C), 129.5, 129.9 (2C), 130.9, 134.4, 135.5, 136.3, 
138.9, 144.7, 170.0, 171.7. 
MS (FAB): m/z (%) = 604 (100) [M + Na+], 604 (100). 
HRMS–FAB: m/z [M + Na]+ calcd for 
C33H43NNaO6S: 604.2709; found: 604.2724.  
 
Supporting Information for this article, including 
experimental procedures and full characterization for 
the substrates and their synthetic intermediates, is 
available online at http://www.thieme-
connect.de/ejournals/toc/synthesis. 
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R1 = alkyl; R2 = alkyl, phenyl, or H; X = NSO2R or C(CO2Et)2  
 
 
Short Title: Palladium-Catalyzed Cascade Cyclization through Direct Arylation 
 
 
 
